Methods of therapy for solid tumors expressing the cd40 cell-surface antigen

Methods of therapy for solid tumors expressing the cd40 cell-surface antigen

  • CN 1,938,045 A
  • Filed: 11/04/2004
  • Published: 03/28/2007
  • Est. Priority Date: 11/04/2003
  • Status: Active Application
First Claim
Patent Images

1. method for the treatment of inflammatory diseases or autoimmune disease patient, described method comprises that the energy specificity that gives described patient'"'"'s effective dose is in conjunction with being expressed in the antigenic people'"'"'s anti-CD 40 of the lip-deep people CD40 of people CD40 express cell monoclonal antibody, described monoclonal antibody does not have tangible agonist activity when in conjunction with the CD40 antigen of described cell surface expression, described people'"'"'s anti-CD 40 monoclonal antibody is selected from:

  • A) monoclonal antibody CHIR-5.9 or CHIR-12.12;

    B) hybridoma cell line 5.9 or 12.12 monoclonal antibodies that produce;

    C) contain the monoclonal antibody that is selected from following aminoacid sequence;

    sequence shown in sequence shown in sequence, the SEQID NO;

    7, the SEQ ID NO;

    8 shown in the SEQ ID NO;

    6, simultaneously contain sequence shown in SEQ ID NO;

    6 and the SEQ IDNO;

    7 and contain SEQ ID NO;

    6 simultaneously and SEQ ID NO;

    8 shown in sequence;

    D) contain the monoclonal antibody that is selected from following aminoacid sequence;

    sequence shown in sequence shown in sequence, the SEQID NO;

    4, the SEQ ID NO;

    5 shown in the SEQ ID NO;

    2, simultaneously contain sequence shown in SEQ ID NO;

    2 and the SEQ IDNO;

    4 and contain SEQ ID NO;

    2 simultaneously and SEQ ID NO;

    5 shown in sequence;

    E) have monoclonal antibody by the aminoacid sequence that contains the nucleic acid molecule encoding that is selected from following nucleotide sequence;

    sequence shown in sequence shown in the SEQ ID NO;

    1, the SEQ ID NO;

    3 and contain SEQ ID NO;

    1 simultaneously and SEQ ID NO;

    3 shown in sequence;

    F) with the monoclonal antibody that can combine with hybridoma cell line 5.9 or the 12.12 bonded epi-positions of monoclonal antibody that produce;

    G) with contain SEQ ID NO;

    10 or the SEQ ID NO;

    12 monoclonal antibody that the epi-position of residue 82-87 of CD40 sequence combines of leting others have a look at;

    H) with contain SEQ ID NO;

    10 or the SEQ ID NO;

    12 monoclonal antibody that the epi-position of residue 82-89 of CD40 sequence combines of leting others have a look at;

    I) monoclonal antibody of in CBA, competing with monoclonal antibody CHIR-5.9 or CHIR-12.12;

    J) each described monoclonal antibody a) described monoclonal antibody or preceding paragraph c of preceding paragraph)-i), wherein said antibody are that reorganization produces;

    WithK) be preceding paragraph a)-j) in the monoclonal antibody of Fab of each described monoclonal antibody, wherein said fragment has kept specificity in conjunction with the antigenic ability of described people CD40.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×